Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 08, 2023 | June 12, 2023 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.67 · Expires 2033-06-08 | Direct | 16,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.
Intellia Therapeutics, Inc.
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,716 |
Reported balance
After 2023-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 4,425 · Balance 11,716 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.20 · Expires 2033-06-13 | Direct | 6,473 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 6,473 · Balance 6,473 F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date January 09, 2024 · Filed March 15, 2024 · Amendment
Section 16 reporting ended · disclosed 2024-03-15. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 927,013 |
Last balance in matching sequence
After 2024-01-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-01-09 · Grant · Acquired 57,620 · Balance 995,492 F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 2 · 2024-01-09 · Tax withholding · Disposed 36,865 · Balance 958,627 F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 3 · 2024-01-10 · Sale · Disposed 31,614 · Balance 927,013 F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 5, 2024 22:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 29,181 | $13.35 | $389,543.01 |
DisclosureSEC source: 0000950170-24-026265 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 573,478 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.04 to $13.58 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:23 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 94,969 | $14.00 | $1,329,566.00 |
DisclosureSEC source: 0000950170-24-017264 · ownership.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 602,659 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:23 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 31,614 | $13.81 | $436,551.40 |
DisclosureSEC source: 0000950170-24-017264 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 697,628 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.36 to $14.02 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:22 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 21,596 | $12.67 | $273,621.32 |
DisclosureSEC source: 0000950170-24-011433 · ownership.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 729,242 Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:22 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 31,614 | $12.62 | $398,918.10 |
DisclosureSEC source: 0000950170-24-011433 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 750,838 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.44 to $12.74 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 22:20 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 55,327 | $12.36 | $683,957.91 |
DisclosureSEC source: 0000950170-24-007065 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,452 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.10 to $12.57 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 22:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 31,614 | $12.78 | $404,105.96 |
DisclosureSEC source: 0000950170-24-005451 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 837,779 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.68 to $12.92 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 23:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 31,614 | $13.65 | $431,452.07 |
DisclosureSEC source: 0000950170-24-004042 · ownership.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 869,393 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 10, 2024 Filed Mar 15, 2024 23:14 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 31,614 | $13.65 | $431,452.07 |
DisclosureSEC source: 0000950170-24-032406 · ownership.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 927,013 F3 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 36,865 | $13.65 | $503,207.25 |
DisclosureSEC source: 0000950170-24-004042 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 901,007 Read SEC document |
| January 09, 2024 Filed Mar 15, 2024 23:14 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 36,865 | $13.65 | $503,207.25 |
DisclosureSEC source: 0000950170-24-032406 · ownership.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 958,627 F2 · balance_after: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Read SEC document |
| January 09, 2024 Filed Mar 15, 2024 23:14 UTC Amendment | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 57,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-032406 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 995,492 F1 · price: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. F2 · balance_after: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 23:02 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 10,659 | $13.44 | $143,256.96 |
DisclosureSEC source: 0000950170-24-002582 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 937,872 Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 23:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 108,417 | $13.53 | $1,466,882.01 |
DisclosureSEC source: 0000950170-24-002130 · ownership.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 948,531 Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 249,665 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0000950170-24-002130 · ownership.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,665 Underlying: Common Stock · 249,665 shares Expires 2034-01-02 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 144,628 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-002130 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,056,948 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 22:55 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 34,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-071631 · ownership.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 912,320 F2 · price: Represents a contingent right to receive common stock in the amount shown, for no consideration, due to the satisfaction of performance criteria underlying an award of performance based restricted stock units granted in 2021. Such units remain outstanding on the date hereof and will fully vest on December 31, 2023, subject to the Reporting Person's continued service with the Company. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 22:55 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,043 | $12.66 | $76,515.86 |
DisclosureSEC source: 0000950170-23-071631 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 877,748 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.51 to $12.83 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,043 | $11.08 | $66,956.44 |
DisclosureSEC source: 0000950170-23-068254 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 883,791 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.88 to $11.21 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:23 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,043 | $10.84 | $65,497.06 |
DisclosureSEC source: 0000950170-23-064910 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 889,834 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.66 to $11.17 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 23:37 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $10.97 | $66,327.46 |
DisclosureSEC source: 0000950170-23-058953 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 895,877 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.865 to $11.08 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 23:57 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $10.50 | $63,449.31 |
DisclosureSEC source: 0000950170-23-054012 · ownership.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 901,921 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.27 to $10.61 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 22:58 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 1,600 | $11.71 | $18,732.00 |
DisclosureSEC source: 0001209191-23-052110 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 907,965 F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.51 to $12.10 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 22:58 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 4,444 | $11.08 | $49,235.08 |
DisclosureSEC source: 0001209191-23-052110 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 909,565 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.95 to $11.47 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 21:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $13.06 | $78,963.65 |
DisclosureSEC source: 0001209191-23-049782 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 914,009 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.93 to $13.22 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $12.98 | $78,447.49 |
DisclosureSEC source: 0001209191-23-048461 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 920,053 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.88 to $13.14 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 21:33 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $13.03 | $78,733.98 |
DisclosureSEC source: 0001209191-23-046081 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 926,097 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.94 to $13.28 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 21:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $13.35 | $80,716.41 |
DisclosureSEC source: 0001209191-23-044494 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 932,141 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.22 to $13.48 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $13.45 | $81,263.39 |
DisclosureSEC source: 0001209191-23-042773 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 938,185 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.32 to $13.70 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 22:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $12.31 | $74,405.87 |
DisclosureSEC source: 0001209191-23-041658 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 944,229 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.26 to $12.46 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:18 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $13.04 | $78,813.76 |
DisclosureSEC source: 0001209191-23-038515 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 950,273 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.86 to $13.35 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:26 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 6,473 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037879 · doc4.xml · derivative · entry 2 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473 Underlying: Common Stock · 6,473 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:26 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 4,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037879 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,716 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $14.67 | $0.00 |
DisclosureSEC source: 0001104659-23-070332 · tm2318445-2_4seq1.xml · derivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:16 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $11.36 | $68,657.42 |
DisclosureSEC source: 0001209191-23-034638 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 956,317 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.08 to $11.51 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:20 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $11.18 | $67,576.76 |
DisclosureSEC source: 0001209191-23-030378 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 962,361 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.93 to $11.44 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:35 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $11.80 | $71,334.91 |
DisclosureSEC source: 0001062993-23-010103 · form4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 968,405 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.59 to $11.89 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 21:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $11.66 | $70,502.05 |
DisclosureSEC source: 0001209191-23-024884 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 974,449 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.50 to $11.91 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $11.22 | $67,787.09 |
DisclosureSEC source: 0001209191-23-023529 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 980,493 F1 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.10 to $11.34 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:39 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $11.34 | $68,547.42 |
DisclosureSEC source: 0001209191-23-019892 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986,537 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.23 to $11.50 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 1,937 | $13.69 | $26,510.17 |
DisclosureSEC source: 0001209191-23-015842 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992,581 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.64 to $13.78 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 4,107 | $13.29 | $54,582.85 |
DisclosureSEC source: 0001209191-23-015842 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994,518 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.64 to $13.63 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 22:49 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 6,044 | $12.94 | $78,217.22 |
DisclosureSEC source: 0001209191-23-010214 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,625 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.36 to $13.34 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 56,596 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-23-007119 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,596 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 83,333 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001209191-23-007119 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,333 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 147,316 | $13.11 | $1,931,342.22 |
DisclosureSEC source: 0001209191-23-007119 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004,669 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022 for estate planning purposes. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.81 to $13.28 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 56,596 | $5.13 | $290,337.48 |
DisclosureSEC source: 0001209191-23-007119 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 83,333 | $6.10 | $508,331.30 |
DisclosureSEC source: 0001209191-23-007119 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 22:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 83,261 | $12.02 | $1,000,797.22 |
DisclosureSEC source: 0001209191-23-003305 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,056 Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 22:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 210,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003305 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,317 F1 · price: Granted for the achievement of the 2020 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.